<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36012469</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>16</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Epipharyngeal Abrasive Therapy (EAT) Reduces the mRNA Expression of Major Proinflammatory Cytokine IL-6 in Chronic Epipharyngitis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9205</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23169205</ELocationID><Abstract><AbstractText>The epipharynx, located behind the nasal cavity, is responsible for upper respiratory tract immunity; however, it is also the site of frequent acute and chronic inflammation. Previous reports have suggested that chronic epipharyngitis is involved not only in local symptoms such as cough and postnasal drip, but also in systemic inflammatory diseases such as IgA nephropathy and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID. Epipharyngeal Abrasive Therapy (EAT), which is an effective treatment for chronic epipharyngitis in Japan, is reported to be effective for these intractable diseases. The sedation of chronic epipharyngitis by EAT induces suppression of the inflammatory cytokines and improves systemic symptoms, which is considered to be one of the mechanisms, but there is no report that has proved this hypothesis. The purpose of this study was to clarify the anti-inflammatory effect of EAT histologically. The study subjects were 8 patients who were not treated with EAT and 11 patients who were treated with EAT for chronic epipharyngitis for 1 month or more. For immunohistochemical assessment, the expression pattern of IL-6 mRNA, which plays a central role in the human cytokine network, was analyzed using in situ hybridization. The expression of IL-6 in the EAT-treated group was significantly lower than those in the EAT nontreated group (<i>p</i> = 0.0015). In addition, EAT suppressed the expression of tumor necrosis factor alpha (TNF&#x3b1;), a crucial proinflammatory cytokine. As a result, continuous EAT suppressed submucosal cell aggregation and reduced inflammatory cytokines. Thus, EAT may contribute to the improvement of systemic inflammatory diseases through the suppression of IL-6 expression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nishi</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4052-0855</Identifier><AffiliationInfo><Affiliation>Section of Otolaryngology, Department of Medicine, Fukuoka Dental College, Fukuoka 814-0193, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nishi Otolaryngology Clinic, Fukuoka 814-0031, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimoto</LastName><ForeName>Shohei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Pathology, Department of Morphological Biology, Division of Biomedical Sciences, Fukuoka Dental College, Fukuoka 814-0193, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oral Medicine Research Center, Fukuoka Dental College, Fukuoka 814-0193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishi</LastName><ForeName>Soichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nishi Otolaryngology Clinic, Fukuoka 814-0031, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishi</LastName><ForeName>Tatsuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Nishi Otolaryngology Clinic, Fukuoka 814-0031, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishi</LastName><ForeName>Ryushiro</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nishi Otolaryngology Clinic, Fukuoka 814-0031, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Section of Otolaryngology, Department of Medicine, Fukuoka Dental College, Fukuoka 814-0193, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsunoda</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imai</LastName><ForeName>Kazuaki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Mirai Clinic, Fukuoka 812-0013, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Tanaka Hiroaki Clinic, Fukuoka 814-0142, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotta</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Internal Medicine, Hotta Osamu Clinic (HOC), Sendai 984-0013, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Ayaki</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tanaka ENT Clinic, Osaka 553-0006, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiromatsu</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-3496-6087</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirasawa</LastName><ForeName>Senji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamano</LastName><ForeName>Takafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Section of Otolaryngology, Department of Medicine, Fukuoka Dental College, Fukuoka 814-0193, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>0000</GrantID><Agency>The Soda Toyoji Memorial Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="Y">Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010612" MajorTopicYN="Y">Pharyngitis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IgA nephropathy</Keyword><Keyword MajorTopicYN="N">epipharyngeal abrasive therapy (EAT)</Keyword><Keyword MajorTopicYN="N">interleukin 6 (IL-6)</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)</Keyword><Keyword MajorTopicYN="N">tumor necrosis factor alpha (TNF&#x3b1;)</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36012469</ArticleId><ArticleId IdType="pmc">PMC9409341</ArticleId><ArticleId IdType="doi">10.3390/ijms23169205</ArticleId><ArticleId IdType="pii">ijms23169205</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hotta O., Inoue C., Tanaka A., Ieiri N. Possible Mechanisms Underlying Epipharyngeal Abrasive Therapy (EAT) with ZnCl2 Solution for the Treatment of Autoimmune Diseases and Functional Somatic Syndrome. J. Antivir. Antiretrovir. 2017;9:81&#x2013;86. doi: 10.4172/1948-5964.1000168.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/1948-5964.1000168</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi K., Nishi R., Kimura S., Nishi S., Tanaka H., Yamano T. Therapeutic effect of epipharyngeal abrasive therapy (EAT) on pharyngeal allergies. Stomato-Pharyngology. 2022;35:372&#x2013;374.</Citation></Reference><Reference><Citation>Nishi K., Yoshimoto S., Nishi S., Tsunoda T., Ohno J., Yoshimura M., Hiromatsu K., Yamano T. Epipharyngeal Abrasive Therapy Down-regulates the Expression of SARS-CoV-2 Entry Factors ACE2 and TMPRSS2. In Vivo. 2022;36:371&#x2013;374. doi: 10.21873/invivo.12712.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/invivo.12712</ArticleId><ArticleId IdType="pmc">PMC8765169</ArticleId><ArticleId IdType="pubmed">34972736</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchi A., Palomba A., El-Mofty S.K. Nasopharynx and Oropharynx. In: Cardesa A., Slootweg P.J., Gale N., Franchi A., editors. Pathology of the Head and Neck. Springer; Berlin/Heidelberg, Germany: 2016. pp. 295&#x2013;331.</Citation></Reference><Reference><Citation>Imai K., Yamano T., Nishi S., Nishi R., Nishi T., Tanaka H., Tsunoda T., Yoshimoto S., Tanaka A., Hiromatsu K., et al. Epipharyngeal Abrasive Therapy (EAT) Has Potential as a Novel Method for Long COVID Treatment. Viruses. 2022;14:907. doi: 10.3390/v14050907.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14050907</ArticleId><ArticleId IdType="pmc">PMC9147901</ArticleId><ArticleId IdType="pubmed">35632649</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogitate M., Sasaki Y., Komiyama A. Outcome of an outpatient specialty clinic for chronic epipharyngitis. Auris Nasus Larynx. 2021;48:451&#x2013;456. doi: 10.1016/j.anl.2020.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anl.2020.09.019</ArticleId><ArticleId IdType="pubmed">33067050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotta O., Tanaka A., Oda T. Chronic epipharyngitis: A missing background of IgA nephropathy. Autoimmun. Rev. 2019;18:835&#x2013;836. doi: 10.1016/j.autrev.2019.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.06.002</ArticleId><ArticleId IdType="pubmed">31176873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotta O., Ieiri N., Inoue C., Tanaka A. Chronic epipharyngitis: A missing trigger in chronic fatigue syndrome. J. Transl. Sci. 2018;4:2&#x2013;3. doi: 10.15761/JTS.1000219.</Citation><ArticleIdList><ArticleId IdType="doi">10.15761/JTS.1000219</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotta O., Oda T. The epipharynx-kidney axis triggers glomerular vasculitis in immunoglobulin A nephropathy. Immunol. Res. 2019;67:304&#x2013;309. doi: 10.1007/s12026-019-09099-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-019-09099-3</ArticleId><ArticleId IdType="pubmed">31745821</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogitate M. Epipharyngeal Abrasive Therapy for Patients with Immunoglobulin A Nephropathy: A Retrospective Study. Sch. J. Otolaryngol. 2022;8:874&#x2013;881.</Citation></Reference><Reference><Citation>Fujimoto M., Katayama K., Nishikawa K., Mizoguchi S., Oda K., Hirabayashi Y., Suzuki Y., Haruki A., Ito T., Murata T., et al. A Kidney Transplant Recipient with Recurrent Henoch-Sch&#xf6;nlein Purpura Nephritis Successfully Treated with Steroid Pulse Therapy and Epipharyngeal Abrasive Therapy. Nephron. 2020;144((Suppl. 1)):54&#x2013;58. doi: 10.1159/000511166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000511166</ArticleId><ArticleId IdType="pubmed">33221802</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res. Ther. 2006;8:S3. doi: 10.1186/ar1917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar1917</ArticleId><ArticleId IdType="pmc">PMC3226076</ArticleId><ArticleId IdType="pubmed">16899107</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi J.F., Lu Z.Y., Jourdan M., Klein B. Interleukin-6 as a therapeutic target. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015;21:1248&#x2013;1257. doi: 10.1158/1078-0432.CCR-14-2291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2291</ArticleId><ArticleId IdType="pubmed">25589616</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes Rivera M., Mastronardi C., Silva-Aldana C.T., Arcos-Burgos M., Lidbury B.A. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review. Diagnostics. 2019;9:91. doi: 10.3390/diagnostics9030091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics9030091</ArticleId><ArticleId IdType="pmc">PMC6787585</ArticleId><ArticleId IdType="pubmed">31394725</ArticleId></ArticleIdList></Reference><Reference><Citation>Raanes E.F.W., Stiles T.C. Associations Between Psychological and Immunological Variables in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A Systematic Review. Front. Psychiatry. 2021;12:716320. doi: 10.3389/fpsyt.2021.716320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2021.716320</ArticleId><ArticleId IdType="pmc">PMC8650213</ArticleId><ArticleId IdType="pubmed">34887782</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Pestka J.J. Attenuation of mycotoxin-induced IgA nephropathy by eicosapentaenoic acid in the mouse: Dose response and relation to IL-6 expression. J. Nutr. Biochem. 2006;17:697&#x2013;706. doi: 10.1016/j.jnutbio.2005.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2005.12.002</ArticleId><ArticleId IdType="pubmed">16524712</ArticleId></ArticleIdList></Reference><Reference><Citation>Groza Y., Jemelkova J., Kafkova L.R., Maly P., Raska M. IL-6 and its role in IgA nephropathy development. Cytokine Growth Factor Rev. 2022;66:1&#x2013;14. doi: 10.1016/j.cytogfr.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2022.04.001</ArticleId><ArticleId IdType="pubmed">35527168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N., Dantzer R., Khandaker G.M. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. 2021;131:105295. doi: 10.1016/j.psyneuen.2021.105295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2021.105295</ArticleId><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotta O., Ieiri N., Nagai M., Tanaka A., Harabuchi Y. Role of Palatine Tonsil and Epipharyngeal Lymphoid Tissue in the Development of Glomerular Active Lesions (Glomerular vasculitis) in Immunoglobulin A Nephropathy. Int. J. Mol. Sci. 2022;23:727. doi: 10.3390/ijms23020727.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23020727</ArticleId><ArticleId IdType="pmc">PMC8775943</ArticleId><ArticleId IdType="pubmed">35054911</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourges D., Wang C.H., Chevaleyre C., Salmon H. T and IgA B lymphocytes of the pharyngeal and palatine tonsils: Differential expression of adhesion molecules and chemokines. Scand J. Immunol. 2004;60:338&#x2013;350. doi: 10.1111/j.0300-9475.2004.01479.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0300-9475.2004.01479.x</ArticleId><ArticleId IdType="pubmed">15379858</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin I., Hotta O., Tani S. Epipharyngeal abrasive therapy in myalgic encephalomyelitis/chronic fatigue syndrome patients. Jpn. J. Clin. Med. 2021;79:989&#x2013;994.</Citation></Reference><Reference><Citation>Tanaka A., Hotta O. The efficacy of Intranasal Sphenopalatine Ganglion Stimulation (INSPGS) in Long COVID, and its Possible Mechanisms. Sch. J. Otolaryngol. 2022;8:860&#x2013;864.</Citation></Reference><Reference><Citation>Harabuchi Y., Takahara M. Recent advances in the immunological understanding of association between tonsil and immunoglobulin A nephropathy as a tonsil-induced autoimmune/inflammatory syndrome. Immun. Inflamm. Dis. 2019;7:86&#x2013;93. doi: 10.1002/iid3.248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.248</ArticleId><ArticleId IdType="pmc">PMC6485698</ArticleId><ArticleId IdType="pubmed">30957421</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka A. Specifics of each method of endoscopic transnasal epipharyngeal abrasive therapy (E-TN-EAT) and endoscopic transoral epipharyngeal abrasive therapy (E-TO-EAT) Stomato-Pharyngology. 2020;33:5&#x2013;16.</Citation></Reference><Reference><Citation>Narazaki M., Kishimoto T. The Two-Faced Cytokine IL-6 in Host Defense and Diseases. Int. J. Mol. Sci. 2018;19:3528. doi: 10.3390/ijms19113528.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19113528</ArticleId><ArticleId IdType="pmc">PMC6274717</ArticleId><ArticleId IdType="pubmed">30423923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int. Immunol. 2020;33:127&#x2013;148. doi: 10.1093/intimm/dxaa078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxaa078</ArticleId><ArticleId IdType="pmc">PMC7799025</ArticleId><ArticleId IdType="pubmed">33337480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto T. IL-6: From its discovery to clinical applications. Int. Immunol. 2010;22:347&#x2013;352. doi: 10.1093/intimm/dxq030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxq030</ArticleId><ArticleId IdType="pubmed">20410258</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X., Huang J., Zhong H., Shen N., Faggioni R., Fung M., Yao Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol. Ther. 2014;141:125&#x2013;139. doi: 10.1016/j.pharmthera.2013.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2013.09.004</ArticleId><ArticleId IdType="pubmed">24076269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A., Fogel A.L., Murphy M.J., Panse G., McGeary M.K., McNiff J.M., Bosenberg M., Vesely M.D., Cohen J.M., Ko C.J., et al. Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis. JID Innov. 2021;1:100021. doi: 10.1016/j.xjidi.2021.100021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xjidi.2021.100021</ArticleId><ArticleId IdType="pmc">PMC8659380</ArticleId><ArticleId IdType="pubmed">34909719</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkatkar T., Du S.W., Jacobs H.M., Dam E.M., Hou B., Buckner J.H., Rawlings D.J., Jackson S.W. B cell&#x2013;derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity. J. Exp. Med. 2017;214:3207&#x2013;3217. doi: 10.1084/jem.20170580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20170580</ArticleId><ArticleId IdType="pmc">PMC5679179</ArticleId><ArticleId IdType="pubmed">28899868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsay A.J., Husband A.J., Ramshaw I.A., Bao S., Matthaei K.I., Koehler G., Kopf M. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science. 1994;264:561&#x2013;563. doi: 10.1126/science.8160012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8160012</ArticleId><ArticleId IdType="pubmed">8160012</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C., Willscher E., Paschold L., Gottschick C., Klee B., Henkes S.S., Bosurgi L., Dutzmann J., Sedding D., Frese T., et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 2022;3:100663. doi: 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantzer R., O&#x2019;Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat. Rev. Neurosci. 2008;9:46&#x2013;56. doi: 10.1038/nrn2297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2297</ArticleId><ArticleId IdType="pmc">PMC2919277</ArticleId><ArticleId IdType="pubmed">18073775</ArticleId></ArticleIdList></Reference><Reference><Citation>Leger-Ravet M.B., Peuchmaur M., Devergne O., Audouin J., Raphael M., Van Damme J., Galanaud P., Diebold J., Emilie D. Interleukin-6 Gene Expression in Castleman&#x2019;s Disease. Blood. 1991;78:2923&#x2013;2930. doi: 10.1182/blood.V78.11.2923.2923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V78.11.2923.2923</ArticleId><ArticleId IdType="pubmed">1954381</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y.F., Yin P., Liu L., Wu S.S., Jia L., Sun S. Effects of APELIN-13 on the expression of IL-6, TNF-&#x3b1;, and IFN-&#x3b3; in rats with experimental autoimmune neuritis. J. Biol. Regul. Homeost Agents. 2019;33:1369&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">31637897</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Y., Wang C., Zhang L. Recent developments and highlights in allergic rhinitis. Allergy. 2019;74:2320&#x2013;2328. doi: 10.1111/all.14067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14067</ArticleId><ArticleId IdType="pubmed">31571226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciprandi G., Silvestri M., Pistorio A., Tosca M.A., Cirillo I. Clustering analysis in outpatients with allergic rhinitis in clinical practice. Allergy. 2019;74:607&#x2013;610. doi: 10.1111/all.13645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.13645</ArticleId><ArticleId IdType="pubmed">30362571</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S., Yu L., Zhang J., Li X., Zhou J., Zeng P., Zhang X. Expression and clinical significance of VCAM-1, IL-6, and IL-17A in patients with allergic rhinitis. Ann. Palliat. Med. 2021;10:4516&#x2013;4522. doi: 10.21037/apm-21-546.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-21-546</ArticleId><ArticleId IdType="pubmed">33966399</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi T., Mitoma H., Harashima S.-i., Tsukamoto H., Shimoda T. Transmembrane TNF-&#x3b1;: Structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49:1215&#x2013;1228. doi: 10.1093/rheumatology/keq031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keq031</ArticleId><ArticleId IdType="pmc">PMC2886310</ArticleId><ArticleId IdType="pubmed">20194223</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratliff M., Alter S., Frasca D., Blomberg B.B., Riley R.L. In senescence, age-associated B cells secrete TNF&#x3b1; and inhibit survival of B-cell precursors. Aging Cell. 2013;12:303&#x2013;311. doi: 10.1111/acel.12055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12055</ArticleId><ArticleId IdType="pmc">PMC3716274</ArticleId><ArticleId IdType="pubmed">23410004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang D.-I., Lee A.-H., Shin H.-Y., Song H.-R., Park J.-H., Kang T.-B., Lee S.-R., Yang S.-H. The Role of Tumor Necrosis Factor Alpha (TNF-&#x3b1;) in Autoimmune Disease and Current TNF-&#x3b1; Inhibitors in Therapeutics. Int. J. Mol. Sci. 2021;22:2719. doi: 10.3390/ijms22052719.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052719</ArticleId><ArticleId IdType="pmc">PMC7962638</ArticleId><ArticleId IdType="pubmed">33800290</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey M., Zhao S.S., Moots R.J. Anti-TNF biosimilars in rheumatology: The end of an era? Expert Opin. Biol. 2021;21:29&#x2013;36. doi: 10.1080/14712598.2020.1802421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2020.1802421</ArticleId><ArticleId IdType="pubmed">32735158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazumdar S., Greenwald D. Golimumab. mAbs. 2009;1:422&#x2013;431. doi: 10.4161/mabs.1.5.9286.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/mabs.1.5.9286</ArticleId><ArticleId IdType="pmc">PMC2759491</ArticleId><ArticleId IdType="pubmed">20065639</ArticleId></ArticleIdList></Reference><Reference><Citation>Melsheimer R., Geldhof A., Apaolaza I., Schaible T. Remicade(&#xae;) (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679695</ArticleId><ArticleId IdType="pubmed">31440029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chima M., Lebwohl M. TNF inhibitors for psoriasis. Semin. Cutan. Med. Surg. 2018;37:134&#x2013;142. doi: 10.12788/j.sder.2018.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.12788/j.sder.2018.039</ArticleId><ArticleId IdType="pubmed">30215629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotta O. Chronic epipharyngitis and its possible focal-infection role. Stomato-Pharyngology. 2010;23:37&#x2013;42.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>